Click here to view the Humana Medical Policy Updates Updates » September 2024 Humana Medical…
BCBS Tennessee Medical Policy Updates – February 2023
Click here to view the Blue Cross Blue Shield BCBS Tennessee Medical Policy Updates »
February 2023 BCBS Tennessee Medical Policy Updates:
- Abdominoplasty with or without Thigh Lift
- Agalsidase Beta (Fabrazyme)
- Alemtuzumab
- Alglucosidase Alfa (Lumizyme)
- Avalglucosidase alfa-ngpt (Nexviazyme)
- Benralizumab
- Biochemical Markers for Alzheimer’s Disease
- Bone Turnover Markers for Diagnosis and Management of Osteoporosis and Other Diseases Associated with High Bone Turnover
- Breast Cancer Gene Expression Assays
- C1 Esterase Inhibitor (Berinert®)
- C1 Esterase Inhibitor (recombinant) – Ruconest®
- Cabazitaxel (Jevtana)
- Carfilzomib
- Cemiplimab-rwlc
- Cerliponase Alfa (Brineura)
- Certolizumab Pegol
- Chelation Therapy
- Computer Assisted Surgical Navigation for Orthopedic Procedures
- Corneal Collagen Cross-Linking
- Cytologic Evaluation in Breast Cancer Risk Assessment
- Diabetes Management
- Dynamic Spinal Visualization
- Ecallantide
- Elapegademase-lvlr (Revcovi)
- Electrical Impedance Scanning of the Breast
- Etranacogene Dezaparvovec-drlb (Hemgenix)
- Fecal Analysis in the Diagnosis of Intestinal Disorders
- Fecal Calprotectin Testing
- Functional Neuromuscular Electrical Stimulation
- Genetic (Human Leukocyte Antigen) Testing for Celiac Disease
- Genetic Testing for Facioscapulohumeral Muscular Dystrophy
- Genetic Testing for Macular Degeneration
- Genetic Testing for Mental Health Conditions
- High Sensitivity C-Reactive Protein (hs-CRP) Testing for Cardiovascular Disease (CVD)
- Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Disease and Venous Thromboembolic Disease
- Hyaluronan Derivatives for Intra-Articular Injection
- Icatibant
- Idursulfase (Elaprase)
- Immune Cell Function Assay
- In Vitro Chemosensitivity and Chemoresistance Assays
- Infliximab
- Intracellular Micronutrient Analysis
- Laronidase (Aldurazyme)
- Lipoprotein-Associated Phospholipase in the Assessment of Cardiovascular Risk
- Measurement of Serum Antibodies to Selected Biologic Agents
- Mirvetuximab Soravtansine-gynx (Elahere™)
- Mogamulizumab-kpkc
- Molecular Markers in Fine Needle Aspirates of the Thyroid
- Mosunetuzumab-axgb (Lunsumio)
- Multitarget Polymerase Chain Reaction (PCR) Testing for the Diagnosis of Bacterial Vaginosis
- Noninvasive Imaging Techniques for Evaluation and Monitoring of Chronic Liver Diseases
- Non-invasive Prenatal Testing Using Cell-free Fetal DNA (cffDNA)
- Novel Biomarkers in Risk Assessment and Management of Cardiovascular Disease
- Obinutuzumab
- Ocrelizumab
- Omalizumab
- Pemetrexed
- Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder (ADHD)
- Quantitative Electroencephalography as a Diagnostic Aid for Attention-Deficit/Hyperactivity Disorder (ADHD)
- Radiotherapy for Prostate Cancer
- Ramucirumab
- Ravulizumab-cwvz
- Rhinomanometry and Acoustic Rhinometry
- Romiplostim (Nplate)
- Salivary Testing for Steroid Hormone Levels
- Sebelipase Alfa (Kanuma)
- Serum Antibodies for the Diagnosis and Management of Inflammatory Bowel Disease
- Serum Holotranscobalamin as a Marker of Vitamin B12 (Cobalamin) Status
- Serum Holotranscobalamin as a Marker of Vitamin B12 (Cobalamin) Status
- Serum Tumor Markers for Breast Malignancies
- Sutimlimab-jome (Enjaymo)
- Teclistamab-cqyv (Tecvayli™)
- Testing Serum Vitamin D Levels
- Testosterone Testing (Total, Free)
- Tezepelumab-ekko (Tezspire™)
- Tocilizumab (Intravenous)
- Total Ankle Replacement
- Trabectedin
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Treatment for Lyme Disease
- Treatment of Tinnitus
- Tremelimumab-actl (Imjudo®)
- Ublituximab-xiiy (Briumvi)
- Upcoming Medical Policies
- Urinary Biomarkers for Screening Bladder Cancer and Precancerous Colon Polyps
- Vestronidase Alfa-vjbk (Mepsevii)
- Vutrisiran (Amvuttra™)
Click here to view the Blue Cross Blue Shield BCBS Tennessee Medical Policy Updates »
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
